Carbonyl stress in schizophrenia

Masanari Itokawa, Mitsuhiro Miyashita, Makoto Arai, Toshio Miyata

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


We have identified idiopathic carbonyl stress in a subpopulation of schizophrenic patients. We first identified a patient with a mutation in GLO1 (glyoxalase I) who showed increased AGE (advanced glycation endproduct) levels and decreased vitamin B6 levels. By applying the observations from this rare case to the general schizophrenic population, we were able to identify a subset of patients (20%) for whom carbonyl stress may represent a causative pathophysiological process. Genetic defects in GLO1 increase the risk of carbonyl stress 5-fold, and the resulting increased AGE levels correlate significantly with PANSS (Positive and Negative Syndrome Scale) scored negative symptoms. Pyridoxamine, an active form of vitamin B6 and scavenger for carbonyl stress, could represent a novel and efficacious therapeutic agent for these treatmentresistant symptoms. In the present article, we describe a unique research approach to identify the causative process in the pathophysiology of a subset of schizophrenia. Our findings could form the basis of a schizophrenia subtype classification within this very heterogeneous disease and ultimately lead to better targeted therapy.

Original languageEnglish
Pages (from-to)468-472
Number of pages5
JournalBiochemical Society Transactions
Issue number2
Publication statusPublished - 2014 Apr


  • Advanced glycation end-product (AGE)
  • Carbonyl stress
  • Glyoxalase I
  • Pyridoxamine
  • Schizophrenia

ASJC Scopus subject areas

  • Biochemistry


Dive into the research topics of 'Carbonyl stress in schizophrenia'. Together they form a unique fingerprint.

Cite this